Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C ≥200 mg/dL (5.1 mmol/L) at screening and the presence of at least 1 of the following criteria:~  * Myocardial infarction (MI)~ * Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)~ * Coronary artery disease documented by angiography or any other accepted imaging technique~ * Positive exercise test (≥1 mm ST-depression at maximal exercise or test terminated because of angina) or a perfusion defect (e.g., thallium or single photon emission computed tomography)~ * Other clinical atherosclerotic diseases: peripheral artery disease, symptomatic carotid artery disease, abdominal aortic aneurysm~ * Or, if alternative above were not met, fasting LDL-C ≥300 mg/dL (7.8 mmol/L)~* On stable, maximally tolerated statin therapy for 8 weeks~* On stable, medication from an additional class of hypolipidemic agents for 8 weeks.~* On stable, low fat diet for 12 weeks~* Stable weight for 6 weeks~Exclusion Criteria:~* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, blood disorders, liver disease, cancer, digestive disorders, Type I diabetes, or uncontrolled Type II diabetes~* Apheresis within 3 months prior to Screening or expected to start apheresis during the treatment phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Weekly subcutaneous injections for 26 weeks
- Mipomersen (Type: EXPERIMENTAL): 200 mg weekly subcutaneous injections for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).